when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog news

Browse

891 stories matching this filter · ← front page

★ save view ↓export CSV

rangeto

sort

recent oldest source alpha

source

STAT815 Endpoints614 BioPharma Dive237 onclive165 Fierce Biotech82 BioSpace80 raps32 globenewswire health26 fda press

therapy area

all Oncology81 Cardiology27 Psychiatry & CNS21 Vaccines17 Immunology17 Rare Disease12 Hepatology6

FDA Accepts sNDA for Taletrectinib in ROS1+ NSCLC
An sNDA with updated data for taletrectinib was accepted by the FDA for TKI-naive and pretreated advanced ROS1+ NSCLC
onclive · 2mo ago↗ source
Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer
onclive · 2mo ago↗ source
Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphoma
Alex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for classical Hodgkin lymphoma and its impact on clinical practice.
onclive · 2mo ago↗ source

page 31 of 36

21

Infectious Disease4

Dr Sznol on Biomarkers of Response in Metastatic Melanoma

Mario Sznol, MD, discusses the uncertainties around predicting benefit with immune checkpoint inhibitors in metastatic melanoma.

onclive · 2mo ago↗ source

Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and Discovery

The State of Utah has made a visionary investment in AI and advanced computing infrastructure to advance research.

onclive · 2mo ago↗ source

Madrigal's Rezdiffra beats estimates; Gilead cuts jobs; Banyan debuts

🚀 Madrigal Pharmaceuticals' MASH drug beats expectations: The biotech’s Rezdiffra sales came in at $311 million for the first quarter, surpassing analysts’ projections by about $10 million, accord…

Endpoints · 2mo ago↗ source

Former Orbital scientists launch new mRNA therapy startup

Two scientists think they've solved a technical problem that has kept the mRNA revolution from reaching its full potential. Now, they're launching ParcelBio with $13 million in seed funding to deve…

Endpoints · 2mo ago↗ source

Avalo scores Phase 2 success in comeback bid, raises $375M

Avalo Therapeutics’ comeback bid surged forward Tuesday afternoon, as the immunology biotech secured a mid-stage trial win in an inflammatory skin disorder. Avalo said that both doses of an experim…

Endpoints · 2mo ago↗ source

ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go

Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.

onclive · 2mo ago↗ source

GSK goes to China for $1B siRNA deal in Arrowhead's obesity lane

GSK is further delving into the cardiometabolic space — and deepening its relationship with China biotechs — in a $1 billion biobucks deal with an siRNA startup. The UK pharma is teaming with Suzho…

Endpoints · 2mo ago↗ source

Consensus Viewpoints Offer Guidance in Rapidly Evolving Multiple Myeloma Management

Ajai Chari, MD, outlines key consensus viewpoints and recommendations for multiple myeloma management from Bridging the Gaps 2025.

onclive · 2mo ago↗ source

Comparing Approved Checkpoint Inhibitor Regimens and Optimal Treatment Duration

New SGO 2026 data shows frontline checkpoint inhibitors deliver 4-year survival gains and near-zero relapse after two years in DMMR cancers.

onclive · 2mo ago↗ source

Disease Assessment and Mutational Testing in Progressive CLL

Experts discuss relapsed CLL workup, using PET-CT and lymph node biopsy to rule out Richter’s, plus resistance testing to guide next therapy.

onclive · 2mo ago↗ source

Clinical Scenario Presentation and Treatment Approach for Progressive Disease

Experts weigh mutation testing, comorbidities, and patient preference to guide second-line CLL options after BTK inhibitor resistance.

onclive · 2mo ago↗ source

Dr Pant on the Mechanism of Action of Daraxonrasib in PDAC

Shubham Pant, MD, MBBS, explains the unique "on-state" binding mechanism of daraxonrasib.

onclive · 2mo ago↗ source

Four-Year Follow-Up Outcomes in dMMR Endometrial Cancer Presented at SGO 2026

SGO 2026 data shows frontline checkpoint inhibitors in dMMR gynecologic cancer drive flat survival curves, hinting at cure and less chemo.

onclive · 2mo ago↗ source

CellCentric raises $220M to get multiple myeloma pill to market

CellCentric has reeled in a massive fund to help it address multiple myeloma patients who have exhausted all other treatment options. The 22-year-old transatlantic biotech has collected a $220 mill…

Endpoints · 2mo ago↗ source

Bayer to buy Perfuse Therapeutics for $300M upfront

Bayer is committing $300 million upfront to buy ophthalmology biotech Perfuse Therapeutics and its mid-stage program targeting the leading causes of blindness. The deal appears to be Bayer’s first…

Endpoints · 2mo ago↗ source

Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressure

A million patients with obesity are already taking Novo Nordisk’s Wegovy pill, CEO Mike Doustdar said Wednesday, despite the market entry of Lilly’s Foundayo. Novo's pill had sales of 2.3 billion D…

Endpoints · 2mo ago↗ source

Simlukafusp Alfa Regimens Show Manageable Safety and Activity But Do Not Outperform SOC in Metastatic RCC

Simlukafusp alfa plus atezolizumab with/without bevacizumab was safe and active but did not improve upon responses with SOC treatments in metastatic RCC.

onclive · 2mo ago↗ source

Dr Cohen on Frontline Chemotherapy Selection in Metastatic Pancreatic Cancer

Deirdre J. Cohen, MD, MS, discusses clinical decision-making and the comparative efficacy of FOLFIRINOX and NALIRIFOX in metastatic pancreatic cancer.

onclive · 2mo ago↗ source

Dr Pant on Managing Toxicities With Daraxonrasib in PDAC

Shubham Pant, MD, MBBS, discusses the management of dermatologic and GI toxicities associated with the RAS(ON) inhibitor daraxonrasib.

onclive · 2mo ago↗ source

Intercept's next-gen FXR agonist fails Phase 2 in latest setback for Italian-owned pharma

Intercept Pharmaceuticals' attempt at creating a next-generation FXR agonist for certain forms of liver inflammation appears to have ended. The drug developer's INT-787 showed "no clear evidence of…

Endpoints · 2mo ago↗ source

Pfizer's Albert Bourla says he has no mega-merger plans

The most candid man in pharma strikes again. When asked on Tuesday’s earnings call whether Pfizer would consider a “transformative M&A” deal in the near or medium term, CEO Albert Bourla said it wo…

Endpoints · 2mo ago↗ source

HS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI Resistance

Phase 1 data show HS-10504 yields encouraging responses and manageable safety in EGFR C797S–mutant NSCLC post TKI therapy.

onclive · 2mo ago↗ source